马来酰胺类糖原合成酶激酶-3β抑制剂的分子对接和三维定量构效关系

通过分子对接和三维定量构效关系(3D-QSAR)两种方法来确定两类马来酰胺类的糖原合成酶激酶-3β(GSK-3β)抑制剂的结合方式.首先,用分子对接确定抑制剂与GSK-3β的结合模式及其相互作用;然后用比较分子力场分析法(CoMFA)与比较分子相似性指数分析法(CoMSIA)对48个化合物做三维定量构效关系的分析.两种方法得出的交互验证回归系数分别为0.669(CoMFA)和0.683(CoMSIA),证明该模型具有很好的统计相关性,同时也说明该模型具有较高的预测能力.根据该模型提供的信息,设计出9个预测性较好的分子.     

五元杂环并嘧啶类胸苷酸合成酶抑制剂的构效关系和分子对接

用比较分子场分析法(CoMFA)和比较分子相似性指数分析法(CoMSIA)研究了38个五元杂环并嘧啶衍生物类胸苷酸合成酶抑制剂的三维定量构效关系(3D-QSAR), 建立了相关预测模型. CoMFA和CoMSIA模型的交互验证相关系数q²分别为0.662和0.672、非交互验证相关系数R²分别为0.921和0.884、外部交互验证相关系数Q_ext²分别为0.85和0.81. 分子对接得到的结合模式与三维定量构效关系得到的结果一致. 结果表明这两种模型都具有良好的预测能力, 可应用于指导化合物的设计和结构修饰, 为进一步设计新型胸苷酸合成酶抑制剂提供了理论依据.     

Combretastatins类微管蛋白抑制剂的定量构效关系与结合模式

以Combretastatins的B环改造化合物为研究对象, 采用遗传函数分析方法进行了二维定量构效关系研究. 研究结果表明, Apol, PMI-mag, Dipole-mag, Hbond donor和RadOfGyration等描述符对该系列抑制剂活性的贡献最大. 采用比较分子场分析方法(CoMFA)和比较分子相似因子分析方法(CoMSIA)进行了三维定量构效关系研究, 建立的CoMFA和CoMSIA模型的交叉验证相关系数q2分别为0.630和0.634, 具有较强的预测能力. 利用CoMFA和CoMSIA模型的三维等势图解析了Combretastatins类化合物的构效关系, 阐明了B环上各取代基对抑制微管蛋白聚合活性的影响, 同时应用分子对接方法分析并验证了定量构效关系模型.     

DATA类逆转录酶抑制剂的三维定量构效关系

采用对接方法得到HIV-1抑制剂DATA(二芳基三嗪类)分子的活性构象, 进一步用比较分子场分析(CoMFA)和比较分子相似性分析(CoMSIA)法对DATA类逆转录酶抑制剂(RTIs)的三维定量构效关系(3D-QSAR)进行了研究, 建立3D-QSAR模型, 以指导进一步结构修饰. 用此模型预测了5个DATA类似物, 预测偏差较小, 表明了所建立的模型具有较强的预测能力.     

新型三唑类抗真菌化合物的三维定量构效关系研究

采用比较分子力场分析法(CoMFA)和比较分子相似性指数分析法(CoMSIA), 系统研究了40个新型三唑类化合物抗真菌活性的三维定量构效关系. 在CoMFA研究中, 研究了两种药效构象对模型的影响, 并考察了网格点步长对统计结果的影响. 在CoMSIA研究中, 系统考察了各种分子场组合、网格点步长和衰减因子对模型统计结果的影响, 发现立体场、静电场、疏水场和氢键受体场的组合得到最佳模型. 所建立CoMFA和CoMSIA模型的交叉相关系数q²值分别为0.718和0.655, 并都具有较强的预测能力. CoMFA和CoMSIA模型的三维等值线图直观地解释了化合物的构效关系, 阐明了化合物结构中苯环上各位置取代基对抗真菌活性的影响, 为进一步结构优化提供了重要依据.     

苯并呋喃类N-肉豆蔻酰基转移酶抑制剂的三维定量构效关系研究

摘要采用比较分子力场分析法(CoMFA)和比较分子相似性指数分析法(CoMSIA), 系统地研究了40个苯并呋喃类N-肉豆蔻酰基转移酶(NMT)抑制剂的三维定量构效关系. 在CoMFA研究中, 考察了网格点步长对模型统计结果的影响. 在CoMSIA研究中, 研究了各种分子场组合、 网格点步长和衰减因子对模型统计结果的影响, 发现立体场、 静电场、 疏水场和氢键受体场的组合可得到最佳模型. 所建立的CoMFA和CoMSIA模型的交叉相关系数q2值分别为0.759和0.730, 均具有较强的预测能力. 利用CoMFA和CoMSIA模型的三维等值线图直观地解释了化合物的构效关系, 阐明了化合物结构中苯并呋喃环上各位置取代基对抑酶活性的影响, 为进一步结构优化提供了重要依据.     

基于分子对接的6-萘甲基取代HEPT类HIV-1逆转录酶抑制剂构效关系研究

采用分子对接方法得到了一系列6-萘甲基取代HEPT类逆转录酶抑制剂分子与HIV-1逆转录酶复合物模型,从中抽取出抑制剂分子的活性构象,进一步应用CoMFA和CoMSIA方法建立了具有较好预测能力的3D-QSAR模型,深入探讨了这些化合物的定量构效关系,为进一步的药物设计奠定了良好的基础.另外,以化合物13及其相应的β异构体24为代表,结合量子化学从头算分子轨道理论方法考察了它们的前线轨道,为阐明α和β系列化合物的活性差异提供了理论依据.     

STAT3环烷烃并噻吩类衍生物抑制剂的三维定量构效关系研究

本文对STAT3抑制剂的化学结构与生物活性之间的关系进行研究。采用三维定量构效关系(3D-QSAR)中的比较分子力场分析(CoMFA)和比较分子相似性指数分析(CoMSIA)方法针对52个STAT3抑制剂建立3D-QSAR模型,阐明了抑制剂化学结构与其生物活性之间的关系。所构建的CoMFA模型交叉验证系数为0.548,非交叉验证系数为0.754,标准偏差为0.278,显著系数为58.297;所构建的CoMSIA模型交叉验证系数为0.892,非交叉验证系数为0.597,标准偏差为0.192,显著系数为57.794。结果显示CoMFA和CoMSIA模型具有良好的稳定性和预测能力。3D-QSAR模型等势图提供的相关场信息对新型STAT3抑制剂的设计具有指导意义。     

含呋喃环双酰脲类衍生物的三维定量构效关系研究

采用比较分子力场分析法(CoMFA)和比较分子相似性指数分析法(CoMSIA), 对27个新型双酰基脲类化合物的杀蚊幼虫(Aedes aegypti L.)活性进行三维定量构效关系(3D-QSAR)研究. 在CoMFA研究中, 考察了网格点步长对统计结果的影响. 在CoMSIA研究中, 系统考察了各种分子场组合、网格点步长和衰减因子对模型统计结果的影响, 发现立体场和氢键供体场的组合得到最佳模型. 所建立的CoMFA和CoMSIA模型的非交叉验证相关系数r2值分别为0.828和0.841, 并都具有较强的预测能力. CoMFA和CoMSIA模型的三维等值图不仅直观地解释了结构与活性的关系, 而且为后续优化该系列化合物提供了理论依据.     

糖原合成激酶-3β马来酰胺类抑制剂构效关系的理论研究

建立糖原合成激酶-3β(GSK-3β)抑制剂的三维构效关系,可预测新的糖原合成激酶-3β抑制剂.通过确定分子的药效构象,与选定的模板分子进行叠合,采用比较分子力场分析法(Co MFA)和比较分子相似性指数分析法(Co MSIA)分别建立38个糖原合成激酶-3β抑制剂的3D-QSAR模型.比较分子力场分析法所建立的模型的决定系数q2=0.711,非交叉验证系数r2=0.887,标准偏差ES=0.411,显著系数F=109.856;比较分子相似性指数分析法所建立模型的决定系数q2=0.605,非交叉验证系数r2=0.931,标准偏差ES=0.326,显著系数F=122.122.该模型在一定程度上反映了结合部位的性质要求,解释马来酰胺类抑制剂的构效关系,具有较好的预测能力.     

In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR,molecular docking and molecular dynamics simulation

Glycogen Synthase Kinase 3 (GSK-3) is a member of cellular kinase with various functions, such as glucose regulation, cellular differentiation, neuronal function and cell apoptosis. It has been proved as an important therapeutic target in type 2 diabetes mellitus and Alzheimer's disease. To better understand their structure–activity relationships and mechanism of action, an integrated computational study, including three dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking, and molecular dynamics (MD), was performed on 79 (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine GSK-3 inhibitors. In this paper, we constructed 3D-QSAR using comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) method. The results showed that the CoMFA model (q ² = 0.743, r² = 0.980) and the CoMSIA model (q² = 0.813, r² = 0.976) had stable and reliable predictive ability. The electrostatic and H-bond donor fields play important roles in the models. The contour maps of the model visually showed the relationship between the activity of compounds and their three-dimensional structure. Molecular docking was used to identify the key amino acid residues at the active site of GSK-3 and explore its binding mode with ligands. Based on 3D-QSAR models, contour maps and the binding feature between GSK-3 and inhibitor, we designed 10 novel compounds with good potential activity and ADME/T profile. Molecular dynamics simulation results validated that Ile62, Val70 and Lys85 located in the active site play a key role for GSK-3 complexed with inhibitors. These results might provide important information for designing GSK-3 inhibitors with high activity.     

A new protocol for predicting novel GSK-3β ATP competitive inhibitors

Glycogen synthase kinase 3β (GSK-3β) is a potential therapeutic target for cancer, type-2 diabetes, and Alzheimer's disease. This paper proposes a new lead identification protocol that predicts new GSK-3β ATP competitive inhibitors with topologically diverse scaffolds. First, three-dimensional quantitative structure-activity relationship (3D QSAR) models were built and validated. These models are based upon known GSK-3β inhibitors, benzofuran-3-yl-(indol-3-yl) maleimides, by means of comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). Second, 28?826 maleimide derivatives were selected from the PubChem database. After filtration via Lipinski's rules, 10?429 maleimide derivatives were left. Third, the FlexX-dock program was employed to virtually screen the 10?429 compounds against GSK-3β. This resulted in 617 virtual hits. Fourth, the 3D QSAR models predicted that from the 617 virtual hits, 93 compounds would have GSK-3β inhibition values of less than 15 nM. Finally, from the 93 predicted active hits, 23 compounds were confirmed as GSK-3β inhibitors from literatures; their GSK-3β inhibition ranged from 1.3 to 480 nM. Therefore, the hits rate of our virtual screening protocol is greater than 25%. The protocol combines ligand- and structure-based approaches and therefore validates both approaches and is capable of identifying new hits with topologically diverse scaffolds.     

Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1

3-Phosphoinositide-dependent protein kinase-1 (PDK1) is a promising target for developing novel anticancer drugs. In order to understand the structure-activity correlation of indolinone-based PDK1 inhibitors, we have carried out a combined molecular docking and three-dimensional quantitative structure-activity relationship (3D-QSAR) modeling study. The study has resulted in two types of satisfactory 3D-QSAR models, including the CoMFA model (r(2)=0.907; q(2)=0.737) and CoMSIA model (r(2)=0.991; q(2)=0.824), for predicting the biological activity of new compounds. The detailed microscopic structures of PDK1 binding with inhibitors have been studied by molecular docking. We have also developed docking-based 3D-QSAR models (CoMFA with q(2)=0.729; CoMSIA with q(2)=0.79). The contour maps obtained from the 3D-QSAR models in combination with the docked binding structures help to better interpret the structure-activity relationship. All of the structural insights obtained from both the 3D-QSAR contour maps and molecular docking are consistent with the available experimental activity data. This is the first report on 3D-QSAR modeling of PDK1 inhibitors. The satisfactory results strongly suggest that the developed 3D-QSAR models and the obtained PDK1-inhibitor binding structures are reasonable for the prediction of the activity of new inhibitors and in future drug design.     

3D-QSAR studies of dihydropyrazole and dihydropyrrole derivatives as inhibitors of human mitotic kinesin Eg5 based on molecular docking

Human mitotic kinesin Eg5 plays an essential role in mitoses and is an interesting drug target against cancer. To find the correlation between Eg5 and its inhibitors, structure-based 3D-quantitative structure-activity relationship (QSAR) studies were performed on a series of dihydropyrazole and dihydropyrrole derivatives using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) methods. Based on the LigandFit docking results, predictive 3D-QSAR models were established, with cross-validated coefficient values (q2) up to 0.798 for CoMFA and 0.848 for CoMSIA, respectively. Furthermore, the CoMFA and CoMSIA models were mapped back to the binding sites of Eg5, which could provide a better understanding of vital interactions between the inhibitors and the kinase. Ligands binding in hydrophobic part of the inhibitor-binding pocket were found to be crucial for potent ligand binding and kinases selectivity. The analyses may be used to design more potent EG5 inhibitors and predict their activities prior to synthesis.     

Receptor-based modeling and 3D-QSAR for a quantitative production of the butyrylcholinesterase inhibitors based on genetic algorithm

Three-dimensional quantitative structure-activity relationship (3D-QSAR) models have been constructed using the comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) for a series of structurally related steroidal alkaloids as butyrylcholinesterase (BuChE) inhibitors. Docking studies were employed to position the inhibitors into the BuChE active site to determine the most probable binding mode. The strategy was to explore multiple inhibitor conformations in producing a more reliable 3D-QSAR model. These multiple conformations were derived using the FlexS program. The conformation selection step for CoMFA was done by genetic algorithm. The genetic algorithm based CoMFA approach was found to be the best. Both CoMFA and CoMSIA yielded significant cross-validated q(2) values of 0.701 and 0.627 and the r(2) values of 0.979 and 0.982, respectively. These statistically significant models were validated by a test set of five compounds. Comparison of CoMFA and CoMSIA contour maps helped to identify structural requirements for the inhibitors and serves as a basis for the design of the next generation of the inhibitor analogues. The results demonstrate that the combination of ligand-based and receptor-based modeling with use of a genetic algorithm is a powerful approach to build 3D-QSAR models. These data can be used for the lead optimization process with respect to inhibition enhancement which is important for the drug discovery and development for Alzheimer's disease.     

Molecular Modeling Studies of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Combining Molecular Docking and 3D-QSAR Methods

The vascular endothelial growth factor (VEGF) and its receptor tyrosine kinases VEGFR-2 or kinase insertdomain receptor (KDR) have emerged as attractive targets for the design of novel anticancer agents. In the present work, molecular docking method combined with three dimensional quantitative structure-activity relationships (comparative molecular field analysis (CoMFA) and comparative molecular similarity indice analysis (CoMSIA)) to analyze the possible interactions between KDR and those derivatives which acted as selective inhibitors. The CoMFA and CoMSIA models gave a cross-validated coefficient Q2 of 0.713 and 0.549, non-cross-validated R2 values of 0.974 and 0.878, and predicted R2 values of 0.966 and 0.823, respectively. The 3D contour maps generated by the CoMFA and CoMSIA models were used to identify the key structural requirements responsible for the biological activity. The information obtained from 3D-QSAR and docking studies were very helpful to design novel selective inhibitors of KDR with desired activity and good chemical property.